Latest Content

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

The FDA issued a nationwide recall of a steroid eye drop.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her session on the hormonal and aesthetic considerations ODs should make when treating these patients.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for Vizz in Australia and New Zealand.

The meeting featured advances in contact lens technology, evolving approaches to keratoconus management, and new insights into dry eye disease treatment.

Ping Moore, OD, outlines modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

Justin Schweitzer, OD, FAAO, details how to distinguish secondary glaucomas from primary glaucomas in a recent presentation.

Jessica Steen, OD, FAAO, DipABO, weighs in on what the optometric community should know concerning what side effects their patients may experience.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.